Experimental surgery gains support as opioid deaths rise

Published 8:18 am Thursday, May 9, 2019

SHANGHAI — Patient Number One is a thin man, with a scabby face and bouncy knees. His head, shaved in preparation for surgery, is wrapped in a clean, white cloth.

Years of drug use cost him his wife, his money and his self-respect, before landing him in this drab yellow room at a Shanghai hospital, facing the surgeon who in 72 hours will drill two small holes in his skull and feed electrodes deep into his brain.

The hope is that technology will extinguish his addiction, quite literally, with the flip of a switch.

Email newsletter signup

The treatment — deep brain stimulation — has long been used for movement disorders like Parkinson’s. Now, the first clinical trial of DBS for methamphetamine addiction is being conducted at Shanghai’s Ruijin Hospital, along with parallel trials for opioid addiction. And this troubled man is the very first patient.

The surgery involves implanting a device that acts as a kind of pacemaker for the brain, electrically stimulating targeted areas. While Western attempts to push forward with human trials of DBS for addiction have foundered, China is emerging as a hub for this research.

Scientists in Europe have struggled to recruit patients for their DBS addiction studies, and complex ethical, social and scientific questions have made it hard to push forward with this kind of work in the United States, where the devices can cost $100,000 to implant.

China has a long, if troubled, history of brain surgery for drug addiction. Even today, China’s punitive anti-drug laws can force people into years of compulsory treatment, including “rehabilitation” through labor. It has a large patient population, government funding and ambitious medical device companies ready to pay for DBS research.

There are eight registered DBS clinical trials for drug addiction being conducted in the world, according to a U.S. National Institutes of Health database. Six are in China.

But the suffering wrought by the opioid epidemic may be changing the risk-reward calculus for doctors and regulators in the United States. Now, the experimental surgery Patient Number One is about to undergo is coming to America. In February, the U.S. Food and Drug Administration greenlighted a clinical trial in West Virginia of DBS for opioid addiction.

Human experiments

Patient Number One insisted that only his surname, Yan, be published; he fears losing his job if he is identified.

He said doctors told him the surgery wasn’t risky. “But I still get nervous,” he said. “It’s my first time to go on the operating table.”

Three of Yan’s friends introduced him to meth in a hotel room shortly after the birth of his son in 2011. They told him: Just do it once, you’ve had your kid, you won’t have problems.

Smoking made Yan feel faint and slightly unhinged. Later, he found meth brought crystalline focus to his mind, which he directed at one thing: Cards. Every time Yan smoked, he gambled. And every time he gambled, he lost — all told, around $150,000 since he started using drugs, he estimated.

His wife divorced him. He rarely saw his son.

Yan checked into a hospital for detox, moved to another town to get away from bad influences, took Chinese traditional medicine. But he relapsed every time. “My willpower is weak,” he said.

Last year his father, who had a friend who had undergone DBS surgery at Ruijin, gave him an ultimatum: Back to rehab or brain surgery. “Of course, I chose surgery,” Yan said. “With surgery, I definitely have the chance to get my life back.”

Before there were brain implants in China there was brain lesioning. Desperate families of heroin users paid thousands of dollars for unproven and risky surgeries in which doctors destroyed small clumps of brain tissue. Brain lesioning quickly became a profit center at some hospitals, but it also left a trail of patients with mood disorders, lost memories and altered sex drives.

In 2004, China’s Ministry of Health ordered a halt to brain lesioning for addiction at most hospitals. Nine years later, doctors at a military hospital in Xi’an reported that roughly half of the 1,167 patients who had their brains lesioned stayed off drugs for at least five years.